A Phase-3 Trial of L-Glutamine in Sickle Cell Disease

Citation metadata

From: The New England Journal of Medicine(Vol. 379, Issue 3)
Publisher: Massachusetts Medical Society
Document Type: Report
Length: 60 words

Document controls

Main content

Abstract :

The study aims to evaluate the safety and efficacy of L-glutamine as a form of treatment for patients with sickle cell disease. The results indicate that among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with L-glutamine, administered alone or in combination with hydroxyurea.

Source Citation

Source Citation   

Gale Document Number: GALE|A547972874